Hansoh Pharmaceutical Proposes Zero-Coupon Convertible Bond Offering, Raising Net Proceeds of Approximately HK$4.64 Billion

Source: JZ Tech

On January 27, Hansoh Pharma announced on the Hong Kong Stock Exchange the proposed issuance of zero-coupon convertible bonds worth HK$4.68 billion maturing in 2033. The initial conversion price is HK$57.39 per share, representing a premium of approximately 42.62% over yesterday's closing price. The bonds can be converted into approximately 81,547,300 shares, accounting for about 1.33% of the enlarged issued share capital.

The net proceeds from the bonds, estimated at approximately HKD 46.40 billion, will be used for drug research and development and licensing, establishing new R&D centers and production lines, upgrading existing R&D and production facilities, as well as for working capital and other general corporate purposes.

Special Statement: The above content only represents the author's viewpoint or position, and does not represent the viewpoint or position of Sina Finance Headlines. If you need to contact Sina Finance Headlines due to issues related to the work's content, copyright, or other matters, please do so within 30 days after the release of the aforementioned content.